Precise and efficient siRNA design: A key point in competent gene silencing

Cancer Gene Therapy

Volumn 23, Issue 4, 2016, Pages 73-82

  Fakhr, E ^a,b   Zare, F ^a,b   Teimoori Toolabi, L ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOTIDE; SMALL INTERFERING RNA; MESSENGER RNA;

ALGORITHM; DRUG DESIGN; GENE SILENCING; NONHUMAN; ONLINE SYSTEM; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; REVIEW; SCORING SYSTEM; TRANSCRIPTION INITIATION SITE; ANIMAL; BINDING SITE; BIOLOGY; CHEMISTRY; DNA BASE COMPOSITION; GENETICS; HUMAN; PROCEDURES; RNA INTERFERENCE; SOFTWARE; WEB BROWSER;

ANIMALS; BASE COMPOSITION; BINDING SITES; COMPUTATIONAL BIOLOGY; GENE SILENCING; HUMANS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SOFTWARE; WEB BROWSER;

EID: 84961218490     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2016.4     Document Type: Review

References (60)

1. Matzke MA, Birchler JA. RNAi-mediated pathways in the nucleus. Nat Rev Genet 2005; 6: 24-35
2. Huppi K, Martin SE, Caplen NJ. Defining and assaying RNAi in mammalian cells. Mol Cell 2005; 17: 1-10
3. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811
4. Guo S, Kemphues KJ. par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell 1995; 81: 611-620
5. Moazeni M, Khoramizadeh MR, Kordbacheh P, Sepehrizadeh Z, Zeraati H, Noorbakhsh F et al. RNA-mediated gene silencing in Candida albicans: inhibition of hyphae formation by use of RNAi technology. Mycopathologia 2012; 174: 177-185
6. Fischer LT, James QY. RNAi, a new therapeutic strategy against viral infection. Cell Res 2004; 14: 460-466
7. de Fougerolles A, Vornlocher H-P, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007; 6: 443-453
8. Yin JQ, Gao J, Shao R, Tian WN, Wang J, Wan Y. siRNA agents inhibit oncogene expression and attenuate human tumor cell growth. J Exp Ther Oncol 2003; 3: 194-204
9. Ambesajir A, Kaushik A, Kaushik JJ, Petros ST. RNA interference: a futuristic tool and its therapeutic applications. Saudi J Biol Sci 2012; 19: 395-403
10. Filippov V, Solovyev V, Filippova M, Gill SS. A novel type of RNase III family proteins in eukaryotes. Gene 2000; 245: 213-221
11. Paddison PJ. RNA interference in mammalian cell systems. Curr Top Microbiol Immunol 2008; 320: 1-19
12. Ji X. The mechanism of RNase III action: how dicer dices. Curr Top Microbiol Immunol 2008; 320: 99-116
13. Rivas FV, Tolia NH, Song J-J, Aragon JP, Liu J, Hannon GJ et al. Purified Argonaute2 and an siRNA form recombinant human RISC. Nat Struct Mol Biol 2005; 12: 340-349
14. Su H, Trombly MI, Chen J, Wang X. Essential and overlapping functions for mammalian Argonautes in microRNA silencing. Genes Dev 2009; 23: 304-317
15. Harborth J, Elbashir SM, Vandenburgh K, Manninga H, Scaringe SA, Weber K et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev 2003; 13: 83-105
16. Taxman DJ, Livingstone LR, Zhang J, Conti BJ, Iocca HA, Williams KL et al. Criteria for effective design, construction, and gene knockdown by shRNA vectors. BMC Biotechnol 2006; 6: 7
17. Takasaki S, Kotani S, Konagaya A. Selecting effective siRNA target sequences for mammalian genes. RNA Biol 2005; 2: 21-27
18. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002; 26: 199-213
19. Teimoori-Toolabi L, Hashemi S, Azadmanesh K, Eghbalpour F, Safavifar F, Khorramizadeh MR. Silencing the wild-Type and mutant K-ras increases the resistance to 5-flurouracil in HCT-116 as a colorectal cancer cell line. Anticancer Drugs 2015; 26: 187-196
20. Ding Y, Lawrence CE. 8 Rational design of siRNAs with the Sfold software. RNA Interference Technology. In: Krishnarao A (ed). From Basic Science to Drug Development. Cambridge University Press: UK, 2005, pp 129-138
21. Van Vranken D, Weiss G. Introduction to Bioorganic Chemistry and Chemical Biology. Garland Science: USA, 2012, pp 155-156
22. Westerhout EM, Berkhout B. A systematic analysis of the effect of target RNA structure on RNA interference. Nucleic Acids Res 2007; 35: 4322-4330
23. Yoshinari K, Miyagishi M, Taira K. Effects on RNAi of the tight structure, sequence and position of the targeted region. Nucleic Acids Res 2004; 32: 691-699
24. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003; 31: 3406-3415
25. Gredell JA, Berger AK, Walton SP. Impact of target mRNA structure on siRNA silencing efficiency: a large-scale study. Biotechnol Bioeng 2008; 100: 744-755
26. Tafer H, Ameres SL, Obernosterer G, Gebeshuber CA, Schroeder R, Martinez J et al. The impact of target site accessibility on the design of effective siRNAs. Nat Biotechnol 2008; 26: 578-583
27. Yu J-Y, DeRuiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci 2002; 99: 6047-6052
28. Paul CP, Good PD, Winer I, Engelke DR. Effective expression of small interfering RNA in human cells. Nat Biotechnol 2002; 20: 505-508
29. Jacque J-M, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 2002; 418: 435-438
30. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553
31. Miyagishi M, Taira K. U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol 2002; 20: 497-500
32. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002; 16: 948-958
33. Lee NS, Dohjima T, Bauer G, Li H, Li M-J, Ehsani A et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002; 20: 500-505
34. Sui G, Soohoo C, Affar EB, Gay F, Shi Y, Forrester WC et al. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci 2002; 99: 5515-5520
35. Yu J-Y, Taylor J, DeRuiter SL, Vojtek AB, Turner DL. Simultaneous inhibition of GSK3α and GSK3β using hairpin siRNA expression vectors. Mol Ther 2003; 7: 228-236
36. Song E, Lee S-K, Wang J, Ince N, Ouyang N, Min J et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347-351
37. Naito Y, Ui-Tei K, Nishikawa T, Takebe Y, Saigo K. siVirus: web-based antiviral siRNA design software for highly divergent viral sequences. Nucleic Acids Res 2006; 34 (suppl 2): W448-W450
38. Kim YJ. Computational siRNA design considering alternative splicing. Methods Mol Biol 2010; 623: 81-92
39. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol 2004; 22: 326-330
40. Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, Juni A et al. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res 2004; 32: 936-948
41. Amarzguioui M, Prydz H. An algorithm for selection of functional siRNA sequences. Biochem Biophys Res Commun 2004; 316: 1050-1058
42. Jagla B, Aluner N, Kelly PD, Song D, Volchuka A, Zatorski A et al. Sequence characteristics of functional siRNAs. RNA 2005; 11: 864-872
43. Ishizuka A, Siomi MC, Siomi H. A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins. Genes Dev 2002; 16: 2497-2508
44. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003; 115: 209-216
45. Donis-Keller H. Site specific enzymatic cleavage of RNA. Nucleic Acids Res 1979; 7: 179-192
46. Hardin CC, Watson T, Corregan M, Bailey C. Cation-dependent transition between the quadruplex and Watson-Crick hairpin forms of d (CGCG3GCG). Biochemistry 1992; 31: 8334
47. Nielsen S, Yuzenkova Y, Zenkin N. Mechanism of eukaryotic RNA polymerase III transcription termination. Science 2013; 340: 1577-1580
48. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001; 20: 6877-6888
49. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21-And 22-nucleotide RNAs. Genes Dev 2001; 15: 188-200
50. Naito Y, Yamada T, Ui-Tei K, Morishita S, Saigo K. siDirect: highly effective, targetspecific siRNA design software for mammalian RNA interference. Nucleic Acids Res 2004; 32(Suppl 2): W124-W129
51. Ui-Tei K, Naito Y, Nishi K, Juni A, Saigo K. Thermodynamic stability and Watson-Crick base pairing in the seed duplex are major determinants of the efficiency of the siRNA-based off-Target effect. Nucleic Acids Res 2008; 36: 7100-7109
52. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequencedependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005; 23: 457-462
53. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11: 263-270
54. Kim D-H, Behlke MA, Rose SD, Chang M-S, Choi S, Rossi JJ. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005; 23: 222-226
55. Lan T, Putta MR, Wang D, Dai M, Yu D, Kandimalla ER et al. Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8. Biochem Biophys Res Commun 2009; 386: 443-448
56. Gheidari F, Bakhshandeh B, Teimoori-Toolabi L, Mehrtash A, Ghadir M, Zeinali S. TCF4 silencing sensitizes the colon cancer cell line to oxaliplatin as a common chemotherapeutic drug. Anticancer Drugs 2014; 25: 908-916
57. Moazeni M, Khoramizadeh MR, Teimoori-Toolabi L, Noorbakhsh F, Rezaie S. The effect of EFG1 gene silencing on down-regulation of SAP5 gene, by use of RNAi technology. Acta Med Iran 2014; 52: 9-14
58. Moazeni M, Khorramizadeh MR, Teimoori-Toolabi L, Noorbakhsh F, Fallahi AA, Rezaie S. Down-regulation of the ALS3 gene as a consequent effect of RNA-mediated silencing of the EFG1 gene in Candida albicans. Iran Biomed J 2012; 16: 172
59. Gomes-da-Silva LC, Fernández Y, Abasolo I, Schwartz S Jr, Ramalho JS, Pedroso de Lima MC et al. Efficient intracellular delivery of siRNA with a safe multitargeted lipid-based nanoplatform. Nanomedicine (Lond) 2013; 8: 1397-1413
60. Kapoor M, Burgess DJ. Efficient and safe delivery of siRNA using anionic lipids: formulation optimization studies. Int J Pharm 2012; 432: 80-90